"Frodo: I wish the Ring had never come to me. I wish none of this had happened.
Gandalf: So do all who live to see such times, but that is not for them to decide. All we have to decide is what to do with the time that is given to us."
- J.R.R. Tolkien
Cannabis Research for Type 1 Diabetes (CR4T1D) is a legally registered, transparent foundation committed to advancing groundbreaking research on the therapeutic potential of cannabis and endocannabinoid system, particularly in the context of Type 1 Diabetes (T1D) and other autoimmune diseases. Our mission is to break down legal and social barriers that hinder cannabis research while fostering international collaboration with leading experts. By conducting and supporting high-quality research, we aim to uncover the mechanisms by which cannabinoids modulate immune function and bring forward new therapeutic strategies.
CR4T1D is committed to educating the public, medical professionals, and policymakers on the potential benefits of cannabis in the treatment of autoimmune conditions. Through these efforts, we strive to pave the way for better patient care, wider access to safe cannabis-based treatments, and ultimately, a new era in the understanding and treatment of T1D. We organize expeditions to regions with favorable legal frameworks, where we can study cannabis therapies in real-world environments.
We believe that phytocannabinoid-based therapies hold the promise to revolutionize the treatment landscape, offering hope for managing immune responses and improving patient outcomes in T1D, and various other diseases of the same background such as rheumatoid arthritis, sclerosis multiplex, psoriasis and others.
We are driven by the belief that this cause has the potential to unite people from all backgrounds, regardless of their perspectives, in pursuit of truth and a shared vision for future generations. Especially in these uncertain times, we aim to foster collaboration and a sense of common purpose to bring forward transformative solutions that will shape a better, healthier world for all.
Cannabis Research for Type 1 Diabetes (CR4T1D) is a legally registered in Poland
NIP: 9532806926
REGON 529880425
KRS: 0001131638
We are currently raising €500,000 to support our groundbreaking 6-month expedition. This funding marks the beginning of our journey, and everything that follows depends on its success. The funds will cover transport, accommodation, supplies, food, essential equipment for creating professional reports, operational costs for the foundation, and salaries for our team members. By securing this financial support, we can ensure that all necessary aspects of the expedition are covered, allowing us to fully focus on our exploration and documentation of cannabis use in a legal, recreational setting.
We are embarking on this expedition with our team of foundation employees, all living with Type 1 Diabetes (T1D), to a country where the recreational use of full-spectrum RSO cannabis oil containing all phytocannabinoids, including 9-delta THC, is legal. This journey allows us to engage with and explore cannabis in real-world settings, gathering personal experiences and valuable insights along the way. With a focus on safety and respect for local laws, we aim to broaden our understanding of cannabis use in type 1 diabetes.
Current Milestones:
We are assembling an expedition of five brave individuals with Type 1 Diabetes who will voluntarily undergo RSO therapy. RSO, or Rick Simpson Oil, is a high-potency extract from Cannabis Indica containing about 60% THC. The therapy involves consuming 60 grams of RSO over a period of 90 days to 6 months, depending on individuals’ tolerance. It was developed by Rick Simpson, whose years of advocacy led to Canada’s eventual legalization of cannabis use. We need 500,000 euros to make this happen. In return, we offer you the truth – whether it is favorable or unfavorable. To uncover this truth, we must challenge existing paradigms, especially those that have placed THC research in the realm of taboo, criminalized it, and surrounded it with senseless regulations designed solely to obscure the reality of its properties. Existing research, both laboratory studies, animal models, and in vitro findings, suggest that THC may play a crucial role in treating autoimmune diseases, such as Type 1 Diabetes, which generate unfathomable profits annually, reaching even trillions of dollars worldwide. It’s time to find out what’s really going on and discover who is truly misleading whom. If our assumptions prove true, I do not hesitate to say that this information could change the course of history. If not- we still win.
Cannabis health radio https://cannabishealthradio.com/podcasts is filled with testimonies from people who have overcome severe cancer or neurological diseases using RSO and high doses of THC. Assuming that Type 1 Diabetes shares many common denominators with the mentioned diseases, and given that cancer treatments are often referenced when developing therapies for T1D, there is a chance that RSO therapy could also be effective in this case. We will conduct the protocol safely, following the guidelines developed by Rick Simpson. In this expedition, I will take on the role of a caretaker and supervisor for these five individuals, ensuring their well-being, proper nutrition, peace, and order. My goal is to create a disturbance-free, comfortable, private, and supportive environment so that they can undergo RSO therapy without any obstacles, for the sake of knowledge, wisdom, and truth for all of us. We will document everything for you and deliver a full report. We will take every precaution, including using CGM (Continuous Glucose Monitoring), to ensure participants are safe and do not experience hypoglycemia or hyperglycemia during the expedition.
After all, the greatest treasures are often guarded by dragons.
|
Accomodation |
50000 |
|
Basic living supplies as food, hygiene |
50000 |
|
Transport |
10000 |
|
Wages |
300000 |
|
Unexpected expenses |
20000 |
|
Operational costs of the foundation |
50000 |
|
Equipment |
20000 |
Welcome to our comprehensive resource center dedicated to the endocannabinoid system (ECS) and its critical role in Type 1 Diabetes (T1D). Here, you will find reliable scientific articles published in top-tier journals, rigorously peer-reviewed, and authored by the world’s leading ECS researchers. These publications provide undeniable evidence of the ECS's involvement in T1D and its complications, as well as its impact on other autoimmune, neurological, and cancer-related conditions. We explore the roles of key phytocannabinoids such as THC, CBD, CBG, THCV, and CBN in modulating the endocannabinoid system and their effects on the bodies of individuals with T1D. However, our primary focus in this section is strictly on Type 1 Diabetes, offering a deep dive into the scientific basis and therapeutic potential of ECS modulation through phytocannabinoids. This library will be continuously expanded and updated as new articles and research become available.
This section also includes a file in .RIS format, which can be opened using reference management software such as Zotero, EndNote, Mendeley, or RefWorks. I personally use Zotero, so I can confirm that it works well with this program. However, I am not certain how the file will open in other programs. For those interested, I recommend getting Zotero to easily browse and manage the collection of over 500 scientific articles I have curated on this topic.
If you've never used a bibliography organizer, I highly recommend Zotero. It's free, works on all operating systems, including Windows and macOS, and offers seamless integration with web browsers like Chrome and Edge. Zotero makes it easy to add references to your library with a simple keyboard shortcut and even provides plugins for MS Word and Google Docs for effortless bibliography management. I highly recommend its use.
If you encounter any difficulties accessing any of the materials, whether those included in the .RIS file or in any other way, please feel free to contact me. I will be more than happy to assist you.
Below, I have included what I consider to be the most impactful articles on the potential use of phytocannabinoids in Type 1 Diabetes (T1D). These articles have significantly shaped the direction of my research and exploration.
https://www.sciencedirect.com/science/article/pii/S0009308400001845
The chemical research on the plant cannabinoids and their derivatives over two centuries is concisely reviewed. The tortuous path leading to the discovery of the endogenous cannabinoids is described. Future directions, which will probably be followed are delineated.
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.13226
Overactive endocannabinoid system contributes to diabetes development by promoting energy intake, impairing glucose and lipid metabolism, and facilitating inflammation in pancreatic islets, with potential therapeutic potential.
https://www.sciencedirect.com/science/article/pii/S104327602200162X
The article titled 'Cannabinoid receptor 2 activation ameliorates inflammation in a mouse model of type 1 diabetes' explores the effects of activating cannabinoid receptor 2 (CB2) on inflammation associated with type 1 diabetes (T1D). Using a mouse model, the study demonstrates that CB2 activation leads to a significant reduction in inflammatory responses, suggesting a potential therapeutic role for CB2 agonists in managing T1D-related inflammation. These findings highlight the importance of the endocannabinoid system in T1D pathophysiology and open avenues for developing novel treatments targeting CB2 receptors.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.809965/full
The article explores the anti-inflammatory and pro-autophagy effects of the cannabinoid receptor CB2R and its potential role in Type 1 Diabetes (T1D). It discusses how CB2R activation might regulate immune responses and prevent β-cell destruction by modulating inflammation and autophagy. The authors suggest that targeting CB2R could be a promising therapeutic strategy to manage or prevent autoimmune processes associated with T1D, without the psychiatric side effects linked to CB1R antagonism.
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.699661/full
The article discusses the presence and role of an autonomous endocannabinoid system (ECS) within the islets of Langerhans. It describes how β-cells have the machinery for ECS signaling, which influences insulin secretion and β-cell stress responses. The review highlights that ECS dysregulation, particularly through CB1 receptors, contributes to β-cell damage and inflammation, emphasizing the potential of targeting ECS components for diabetes treatment. Further research is needed to translate these findings into clinical practice.
https://link.springer.com/article/10.1007/s00125-007-0890-y
The study published in Diabetologia discusses the role of the endocannabinoid system (ECS) in obesity and diabetes. It focuses on the involvement of cannabinoid receptors (CB1 and CB2) and how dysregulation of the ECS affects glucose and lipid metabolism, promoting conditions like obesity and 2 Diabetes both, Type 1 and 2. The paper also explores the therapeutic potential of targeting CB1 receptors to mitigate metabolic complications.
https://joe.bioscientifica.com/view/journals/joe/211/2/177.xml
The article investigates the role of the G protein-coupled receptor GPR55, considered as endocannabinoid receptor, in the islets of Langerhans, specifically in insulin-secreting β-cells. It finds that GPR55 activation increases intracellular calcium and enhances glucosestimulated insulin secretion, indicating its involvement in glucose homeostasis. This suggests GPR55 as a potential target for managing type 2 diabetes and metabolic disorders.
https://doi.org/10.1007/s11892-018-0975-7
The article titled 'Cannabinoid Receptors in Diabetic Kidney Disease' reviews the relevance of the endocannabinoid system in diabetic kidney disease (DKD). It explains that endocannabinoids and CB1/CB2 receptors are altered in DKD, and preclinical studies show that CB1 receptor blockade and CB2 receptor activation can alleviate kidney damage in diabetes. These findings suggest that targeting the ECS could be a potential therapeutic strategy for DKD, although further research is needed before clinical applications.
Pierwszy wpis będzie dotyczył tego, że jesteśmy już LIVE, zapraszamy na zbiórki
1. What does the Cannabis Research for Type 1 Diabetes Foundation do?
The foundation focuses on researching the potential impact of RSO (Rick Simpson Oil) on the health and quality of life of individuals with Type 1 Diabetes. Our goal is to gather funds and conduct empirical research in this area.
2. Are the foundation's studies considered clinical trials?
No, our project is not a clinical trial. RSO is legally available in countries where recreational use is permitted, and we conduct our research under these conditions to explore its effects on quality of life and health.
3. How can I support the foundation?
Every contribution is valuable to us. You can support us financially, help spread information about our activities, or get involved as a volunteer or project ambassador.
4. What are the foundation's goals for the near future?
Our immediate goal is to organize a six-month research project that will allow us to collect data on the impact of cannabis oil on the quality of life of individuals with Type 1 Diabetes. We also plan to raise awareness about the potential health benefits of cannabis and build a support community.
5. Who will be testing RSO products as part of the foundation's project, and how will it be done?
In our project, only adults who are employees of the foundation and live with Type 1 Diabetes will participate in reviewing legal cannabis products, including full spectrum THC rich RSO, available on the recreational market in the Netherlands. Our goal is to collect their personal observations regarding the impact of recreational cannabis use on quality of life and blood glucose levels.
We emphasize that this is an exploratory project, focusing on health promotion and sharing user experiences rather than conducting clinical trials. All participants use cannabis products legally, in compliance with local regulations, and this is not formal medical testing but rather the collection of individual opinions based on personal experiences.
6. Do foundation employees test cannabis products?
We do not conduct formal product testing. The foundation’s employees, who live with Type 1 Diabetes, review cannabis products available on the market and share their observations on how these products affect their quality of life and blood glucose levels. The aim is to gather individual experiences and better understand the potential benefits of alternative health support methods, not to conduct clinical trials.
7. What are the benefits of switching from smoking cannabis to consuming FECO (Full Extract Cannabis Oil)?
Our research aims to understand how changing the form of cannabis consumption, for example, from smoking to using FECO (Full Extract Cannabis Oil), impacts quality of life and health. FECO oils may offer more stable and long-lasting effects and may reduce the risks associated with smoking.
Our mission is to share knowledge based on personal experiences. We believe that everyone has the right to responsibly and consciously explore the potential benefits that cannabis can offer—always within legal boundaries and with a focus on health.
We are committed to promoting safe and responsible use of legally available cannabis products. Our goal is to maximize health benefits through mindful consumption and exploration of alternative ways to enhance quality of life.
Our Values:
Our foundation is guided by these values to create a safe and informed space for everyone interested in the potential impact of cannabis on health and quality of life.